This report analyzes the disruptive themes that have driven M&A activity in 2021 in the Pharma Sector
M&A deal value in global Pharma sector grew by 15%, from $191 billion in 2020 to $219 billion in 2021. In terms of deal volume, 2021 saw 908 deals compared to 795 in the previous year, recording a growth of 14%. There were 44 billion-dollar-plus M&A deals in the pharma sector in 2021, compared to 28 in the previous year.
M&A deal value in global Pharma sector grew by 15%, from $191 billion in 2020 to $219 billion in 2021. In terms of deal volume, 2021 saw 908 deals compared to 795 in the previous year, recording a growth of 14%. There were 44 billion-dollar-plus M&A deals in the pharma sector in 2021, compared to 28 in the previous year.
Scope
- This report provides an overview of merger and acquisition activity globally in 2021 in Pharma Sector
- It identifies the themes driving most notable to deals announced in 2021 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in Pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Global M&A deals in 2021 - Key takeaways
- Review of global M&A deals in 2021
- Themes driving global M&A deals in 2021
- Appendices
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk
- Merck & Co
- Perrigo Co
- Sanofi
- Pfizer
- EQRx
- Bayer
- Amgen
- PerkinElmer
- Vitrolife
- Danaher
- MorphoSys
- Thermo Fisher Scientific
- ICON
- Jazz Pharmaceuticals
- Horizon Therapeutics
- Dicerna Pharmaceuticals
- Acceleron Pharma
- Laboratoire HRA Pharma
- Kadmon Holdings
- Trillium Therapeutics
- CM Life Sciences III
- Vividion Therapeutics
- Translate Bio
- TeneoBio
- Biolegend
- Igenomix
- Aldevron
- Constellation Pharmaceuticals
- PPD
- Five Prime Therapeutics
- Pandion Therapeutics
- PRA Health Sciences
- GW Pharmaceuticals
- Viela Bio
- Kymab
- Laboratory Corp of America
- Novartis
- Synthetic Biologics
- Pacira BioSciences
- ProPhase Labs
- XOMA
- UniQure
- Brooklyn ImmunoTherapeutics
- Nexturn Bio
- XERIS Pharmaceuticals
- Roivant Sciences
- Royalty Pharma
- Renovacor
- Intec Pharma
- VG Acquisition
- Ensysce Biosciences
- Personal Genome Diagnostics
- Gyroscope Therapeutics
- VCN Biosciences
- Flexion Therapeutics
- Nebula Genomics
- Kuros Biosciences
- Corlieve Therapeutics
- Novellus Therapeutics
- RosVivo Therapeutics
- Strongbridge Biopharma
- Montes Archimedes
- Tidal Therapeutics
- Chardan Healthcare Acquisition
- Decoy Biosystems
- 23andMe
- CSL
- StepStone Group
- Triley Bidco
- Murano Bidco
- Amunix Operating
- Vifor Pharma
- Arena Pharmaceuticals
- Clinigen Group
- CM Life Sciences III
- Vectura Group
- Vaccitech
- Sagard Holdings
- Beijing Pharmaceutical Investment and Management
- Catalent
- Compass Therapeutics
- Athenex
- Takeda Pharmaceutical
- Grifols
- Celularity
- Avidea Technologies
- AnaptysBio
- Immunotech Biopharm
- RheinCell Therapeutics
- TRIGR Therapeutics
- Kuur Therapeutics
- Montes Archimedes Acquisition
- Maverick Therapeutics
- GigaGen
- Silicon Therapeutics
- GX Acquisition
